Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Current Assets: 2019-2024

Historic Current Assets for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $588.9 million.

  • Keros Therapeutics' Current Assets rose 30.30% to $719.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $719.3 million, marking a year-over-year increase of 30.30%. This contributed to the annual value of $588.9 million for FY2024, which is 69.57% up from last year.
  • Latest data reveals that Keros Therapeutics reported Current Assets of $588.9 million as of FY2024, which was up 69.57% from $347.3 million recorded in FY2023.
  • Keros Therapeutics' 5-year Current Assets high stood at $588.9 million for FY2024, and its period low was $251.4 million during FY2021.
  • Over the past 3 years, Keros Therapeutics' median Current Assets value was $347.3 million (recorded in 2023), while the average stood at $407.3 million.
  • Per our database at Business Quant, Keros Therapeutics' Current Assets spiked by 2,899.06% in 2020 and then decreased by 6.08% in 2021.
  • Keros Therapeutics' Current Assets (Yearly) stood at $267.7 million in 2020, then decreased by 6.08% to $251.4 million in 2021, then grew by 13.65% to $285.8 million in 2022, then grew by 21.53% to $347.3 million in 2023, then skyrocketed by 69.57% to $588.9 million in 2024.